JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

CytomX Therapeutics Inc

Затворен

СекторЗдравеопазване

3.26

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.24

Максимум

3.2800000000000002

Ключови измерители

By Trading Economics

Приходи

-24M

-154K

Продажби

-32M

19M

P/E

Средно за сектора

7.48

37.461

Марж на печалбата

-0.825

Служители

119

EBITDA

-24M

-939K

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+68.71% upside

Дивиденти

By Dow Jones

Следващи печалби

6.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

240M

617M

Предишно отваряне

3.26

Предишно затваряне

3.26

Настроения в новините

By Acuity

23%

77%

46 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

CytomX Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.10.2025 г., 18:41 ч. UTC

Печалби

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24.10.2025 г., 18:31 ч. UTC

Печалби

Correction to Procter & Gamble to Focus on Innovation

24.10.2025 г., 16:25 ч. UTC

Значими двигатели на пазара

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24.10.2025 г., 21:24 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

24.10.2025 г., 21:24 ч. UTC

Пазарно говорене

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24.10.2025 г., 21:07 ч. UTC

Печалби

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24.10.2025 г., 20:58 ч. UTC

Печалби

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

24.10.2025 г., 20:40 ч. UTC

Печалби

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24.10.2025 г., 20:24 ч. UTC

Печалби

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24.10.2025 г., 20:23 ч. UTC

Печалби

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24.10.2025 г., 20:13 ч. UTC

Печалби

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24.10.2025 г., 20:07 ч. UTC

Пазарно говорене

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24.10.2025 г., 19:40 ч. UTC

Пазарно говорене

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24.10.2025 г., 19:35 ч. UTC

Пазарно говорене

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24.10.2025 г., 19:33 ч. UTC

Печалби

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24.10.2025 г., 19:29 ч. UTC

Пазарно говорене

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24.10.2025 г., 18:52 ч. UTC

Печалби

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24.10.2025 г., 18:41 ч. UTC

Печалби

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24.10.2025 г., 18:03 ч. UTC

Печалби

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24.10.2025 г., 18:02 ч. UTC

Печалби

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24.10.2025 г., 18:00 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24.10.2025 г., 16:57 ч. UTC

Печалби

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24.10.2025 г., 16:54 ч. UTC

Пазарно говорене

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24.10.2025 г., 16:44 ч. UTC

Пазарно говорене
Печалби

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24.10.2025 г., 16:39 ч. UTC

Пазарно говорене
Печалби

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24.10.2025 г., 16:33 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24.10.2025 г., 16:23 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

24.10.2025 г., 16:07 ч. UTC

Печалби

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

CytomX Therapeutics Inc Прогноза

Ценова цел

By TipRanks

68.71% нагоре

12-месечна прогноза

Среден 5.5 USD  68.71%

Висок 7 USD

Нисък 3.5 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за CytomX Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

7

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

0.7658 / N/AПодкрепа & съпротива

Краткосрочен план

Strong Bullish Evidence

Средносрочен план

Very Strong Bullish Evidence

Дългосрочен план

Weak Bullish Evidence

Настроение

By Acuity

46 / 371 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
help-icon Live chat